Michael Morrissey on refugee crisis
From ECO’s Mike Morrissey: Ukraine is a priority of our lifetime in oncology · · The Cancer Letter
“We need to start thinking about the medium to long term of this crisis because not all refugees will return, and cancer healthcare systems will need to manage equity between nationals and Ukrainian refugees.”
On , Michael Morrissey, Chief Executive Officer, President & Director at EXELIXIS INC, spoke about refugee crisis during ECO’s Mike Morrissey: Ukraine is a priority of our lifetime in oncology on The Cancer Letter.
About Michael Morrissey
Michael Morrissey, as president and CEO of Exelixis, discussed the company's first quarter 2025 financial results in May 2025, reporting net product revenue of $513.3 million, a 36% year-over-year increase. He stated that the company was "excited about the trajectory of our business" and noted that Exelixis was increasing its full-year 2025 net product revenue guidance to between $2.05 billion and $2.15 billion. Morrissey also highlighted the approval of CABOMETYX for neuroendocrine tumors and said the company was advancing its pipeline, including the ZANZA trials. In December 2025, Morrissey, in his role as Norfolk District Attorney, spoke publicly for the first time since the conclusion of the Karen Read trial. He said that he was "much happier with the outcome today" regarding the Brian Walshe murder trial and expressed satisfaction with the work of law enforcement and his office. Morrissey explained his previous silence by stating that speaking out could "interfere with an individual's right to a fair trial." He added that he took the job "to speak for victims" and would continue to focus on that through his tenure.